Compare · JNJ vs PRGO
JNJ vs PRGO
Side-by-side comparison of Johnson & Johnson (JNJ) and Perrigo Company plc (PRGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PRGO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $549.78B, about 387.6x PRGO ($1.42B).
- Over the past year, JNJ is up 52.4% and PRGO is down 61.3% - JNJ leads by 113.8 points.
- Both names hit the wire about 15 times in the past 4 weeks.
- JNJ has more recent analyst coverage (25 ratings vs 11 for PRGO).
- Company
- Johnson & Johnson
- Perrigo Company plc
- Price
- $228.34-2.38%
- $10.25+0.89%
- Market cap
- $549.78B
- $1.42B
- 1M return
- -0.78%
- -3.44%
- 1Y return
- +52.43%
- -61.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 15
- 15
- Recent ratings
- 25
- 11
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Latest JNJ
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
- EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Latest PRGO
- Director Parker Geoffrey M. exercised 976 units of Ordinary Shares at a strike of $10.99 and covered exercise/tax liability with 469 units of Ordinary Shares, increasing direct ownership by 2% to 33,217 units (SEC Form 4)
- SEC Form 4 filed by Interim President and CEO Manzone Albert
- Director Alford Bradley A exercised 976 units of Ordinary Shares at a strike of $10.99 and covered exercise/tax liability with 469 units of Ordinary Shares, increasing direct ownership by 1% to 45,465 units (SEC Form 4)
- SEC Form SD filed by Perrigo Company plc
- Former CEO and director Lockwood-Taylor Patrick exercised 25,230 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 12,906 units of Ordinary Shares, increasing direct ownership by 11% to 123,170 units (SEC Form 4)
- Perrigo Company plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Perrigo Announces Leadership Transition
- EVP and President of CSCI Khoury Roberto exercised 17,902 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 9,346 units of Ordinary Shares, increasing direct ownership by 164% to 13,761 units (SEC Form 4)
- EVP & CHRO Willis Robert exercised 3,441 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 1,797 units of Ordinary Shares, increasing direct ownership by 3% to 50,568 units (SEC Form 4)
- EVP and CSO Lennox Abigail exercised 3,823 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 1,996 units of Ordinary Shares, increasing direct ownership by 66% to 4,607 units (SEC Form 4)